In March 2007, Novartis suspended marketing of tega-serod maleate (Zelnorm), an agonist
for the 5-HT4 serotonin receptor used for patients with irritable bowel syndrome (IBS) and …

Background Tegaserod, a 5-HT4 agonist, is effective for treating irritable bowel syndrome
and chronic constipation. However, sales of this drug were recently suspended due to …

Tegaserod is a first-in class selective serotonin 4 receptor agonist approved for the treatment
of irritable bowel syndrome. In March 2007, the US Food and Drug Administration (FDA) …

OBJECTIVES: Tegaserod is a selective serotonin (5-HT 4) receptor partial agonist effective
in providing relief from abdominal pain, bloating, and constipation in patients with irritable …

Background: Tegaserod is a 5‐hydroxytryptamine‐4 receptor partial agonist. Oral
administration causes gastrointestinal effects resulting in increased gastrointestinal motility …

Background: Tegaserod (Zelnorm®) is a 5-hydroxytryptamine (serotonin) type 4 receptor
agonist for the treatment of hypomotility disorders of the lower gastrointestinal tract …

Objective To evaluate the safety/tolerability and efficacy of tegaserod, a 5-HT 4 receptor
partial agonist, in the treatment of patients with non-diarrhoea irritable bowel syndrome (non …

Tegaserod is a medication that has been shown to be of benefit in women with irritable
bowel syndrome (IBS) associated with abdominal pain, bloating, and constipation …

Background: Tegaserod (HTF 919) is a selective 5‐HT4 receptor partial agonist in
development for the treatment of irritable bowel syndrome. Aim: This study aimed to assess …

The treatment of irritable bowel syndrome with constipation (IBS-C) has historically been
based on the severity of symptoms, with education, reassurance, dietary advice, bulking …